{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:44:40Z","timestamp":1789958680340,"version":"4.0.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:00:00Z","timestamp":1724371200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007625","name":"Cure Alzheimer's Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007625","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007457","name":"JPB Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007457","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["RF1NS090934"],"award-info":[{"award-number":["RF1NS090934"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U19AG069701"],"award-info":[{"award-number":["U19AG069701"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P01 AG078106"],"award-info":[{"award-number":["P01 AG078106"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","bmn.com","cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Immunology"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.it.2024.08.001","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T08:11:24Z","timestamp":1726301484000},"page":"768-782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["New insights into innate immunity in Alzheimer\u2019s disease: from APOE protective variants to therapies"],"prefix":"10.1016","volume":"45","author":[{"given":"Yun","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3400-0856","authenticated-orcid":false,"given":"David M.","family":"Holtzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.it.2024.08.001_bb0005","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer\u2019s disease facts and figures","volume":"19","author":"Anon.","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.it.2024.08.001_bb0010","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The path forward in Alzheimer\u2019s disease therapeutics: reevaluating the amyloid cascade hypothesis","volume":"16","author":"Tolar","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.it.2024.08.001_bb0015","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41593-020-0687-6","article-title":"Synergy between amyloid-\u03b2 and tau in Alzheimer\u2019s disease","volume":"23","author":"Busche","year":"2020","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.it.2024.08.001_bb0020","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","article-title":"Emerging diagnostics and therapeutics for Alzheimer disease","volume":"29","author":"Self","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in early Alzheimer\u2019s disease","volume":"388","author":"van Dyck","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0030","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER-ALZ 2 randomized clinical trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.it.2024.08.001_bb0035","doi-asserted-by":"crossref","first-page":"4260","DOI":"10.1016\/j.cell.2023.08.021","article-title":"Alzheimer\u2019s disease: from immunotherapy to immunoprevention","volume":"186","author":"Jucker","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.it.2024.08.001_bb0040","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbd.2003.09.015","article-title":"Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration","volume":"15","author":"Wilcock","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.it.2024.08.001_bb0045","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41582-020-00435-y","article-title":"Neuroinflammation and microglial activation in Alzheimer disease: where do we go from here?","volume":"17","author":"Leng","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.it.2024.08.001_bb0050","first-page":"416","article-title":"A TREM2-activating antibody with a blood-brain barrier transport vehicle enhances microglial metabolism in Alzheimer\u2019s disease models","volume":"26","author":"van Lengerich","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.it.2024.08.001_bb0055","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.201911227","article-title":"Enhancing protective microglial activities with a dual function TREM2 antibody to the stalk region","volume":"12","author":"Schlepckow","year":"2020","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0060","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S1474-4422(23)00247-8","article-title":"Stimulation of TREM2 with agonistic antibodies-an emerging therapeutic option for Alzheimer\u2019s disease","volume":"22","author":"Schlepckow","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.it.2024.08.001_bb0065","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.it.2024.08.001_bb0075","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuron.2012.10.029","article-title":"A plaque-specific antibody clears existing \u03b2-amyloid plaques in Alzheimer\u2019s disease mice","volume":"76","author":"Demattos","year":"2012","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0080","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj9052","article-title":"Antibody-mediated targeting of human microglial leukocyte Ig-like receptor B4 attenuates amyloid pathology in a mouse model","volume":"16","author":"Hou","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0085","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s13024-023-00649-w","article-title":"Amyloid-\u03b2 (A\u03b2) immunotherapy induced microhemorrhages are associated with activated perivascular macrophages and peripheral monocyte recruitment in Alzheimer\u2019s disease mice","volume":"18","author":"Taylor","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.it.2024.08.001_bb0090","doi-asserted-by":"crossref","first-page":"10868","DOI":"10.1038\/s41598-024-61691-2","article-title":"Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities","volume":"14","author":"S\u00f6derberg","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.it.2024.08.001_bb0095","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13195-024-01441-8","article-title":"Updated safety results from phase 3 lecanemab study in early Alzheimer\u2019s disease","volume":"16","author":"Honig","year":"2024","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.it.2024.08.001_bb0100","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer\u2019s disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0105","doi-asserted-by":"crossref","first-page":"562","DOI":"10.2214\/AJR.22.28461","article-title":"Amyloid-related imaging abnormalities: an update","volume":"220","author":"Roytman","year":"2023","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.it.2024.08.001_bb0110","first-page":"211","article-title":"Detection and management of amyloid-related imaging abnormalities in patients with Alzheimer\u2019s disease treated with anti-amyloid beta therapy","volume":"9","author":"Barakos","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.it.2024.08.001_bb0115","doi-asserted-by":"crossref","first-page":"873","DOI":"10.3233\/ADR-230025","article-title":"Antibody-mediated clearance of brain amyloid-\u03b2: mechanisms of action, effects of natural and monoclonal anti-A\u03b2 antibodies, and downstream effects","volume":"7","author":"Loeffler","year":"2023","journal-title":"J. Alzheimers Dis. Rep."},{"key":"10.1016\/j.it.2024.08.001_bb0120","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.862369","article-title":"Amyloid-related imaging abnormalities with anti-amyloid antibodies for the treatment of dementia due to Alzheimer\u2019s disease","volume":"13","author":"Withington","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.it.2024.08.001_bb0125","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1146\/annurev.ne.19.030196.000413","article-title":"Apolipoprotein E and Alzheimer\u2019s disease","volume":"19","author":"Strittmatter","year":"1996","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.it.2024.08.001_bb0130","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: an update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.it.2024.08.001_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2022.101594","article-title":"APOE mediated neuroinflammation and neurodegeneration in Alzheimer\u2019s disease","volume":"59","author":"Parhizkar","year":"2022","journal-title":"Semin. Immunol."},{"key":"10.1016\/j.it.2024.08.001_bb0140","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/j.neuron.2022.03.004","article-title":"ApoE Cascade Hypothesis in the pathogenesis of Alzheimer\u2019s disease and related dementias","volume":"110","author":"Martens","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0145","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1073\/pnas.050004797","article-title":"Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer\u2019s disease","volume":"97","author":"Holtzman","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2024.08.001_bb0150","doi-asserted-by":"crossref","first-page":"8098","DOI":"10.1073\/pnas.90.17.8098","article-title":"Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease","volume":"90","author":"Strittmatter","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2024.08.001_bb0155","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0694-180","article-title":"Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease","volume":"7","author":"Corder","year":"1994","journal-title":"Nat. Genet."},{"key":"10.1016\/j.it.2024.08.001_bb0160","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","article-title":"ApoE4 accelerates early seeding of amyloid pathology","volume":"96","author":"Liu","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0165","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.immuni.2017.08.008","article-title":"The TREM2-APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases","volume":"47","author":"Krasemann","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.it.2024.08.001_bb0170","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","article-title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy","volume":"549","author":"Shi","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.it.2024.08.001_bb0175","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.neuron.2022.10.022","article-title":"TREM2-independent microgliosis promotes tau-mediated neurodegeneration in the presence of ApoE4","volume":"111","author":"Gratuze","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0180","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1038\/s41590-023-01627-6","article-title":"APOE4 impairs the microglial response in Alzheimer\u2019s disease by inducing TGF\u03b2-mediated checkpoints","volume":"24","author":"Yin","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2024.08.001_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.113183","article-title":"ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes","volume":"42","author":"Lee","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2024.08.001_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111200","article-title":"APOE4 drives inflammation in human astrocytes via TAGLN3 repression and NF-\u03baB activation","volume":"40","author":"Arnaud","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2024.08.001_bb0195","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1038\/s41586-022-05439-w","article-title":"APOE4 impairs myelination via cholesterol dysregulation in oligodendrocytes","volume":"611","author":"Blanchard","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.it.2024.08.001_bb0200","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1038\/s41590-023-01640-9","article-title":"Cell-autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer\u2019s disease","volume":"24","author":"Liu","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.it.2024.08.001_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2022.105615","article-title":"APOE4 confers transcriptomic and functional alterations to primary mouse microglia","volume":"164","author":"Machlovi","year":"2022","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.it.2024.08.001_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108572","article-title":"ApoE4 impairs neuron-astrocyte coupling of fatty acid metabolism","volume":"34","author":"Qi","year":"2021","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2024.08.001_bb0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz4564","article-title":"APOE4 disrupts intracellular lipid homeostasis in human iPSC-derived glia","volume":"13","author":"Sienski","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0220","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/j.cell.2022.05.017","article-title":"Cholesterol and matrisome pathways dysregulated in astrocytes and microglia","volume":"185","author":"Tcw","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.it.2024.08.001_bb0225","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.stem.2022.07.005","article-title":"Lipid accumulation induced by APOE4 impairs microglial surveillance of neuronal-network activity","volume":"29","author":"Victor","year":"2022","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.it.2024.08.001_bb0230","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-024-07185-7","article-title":"APOE4\/4 is linked to damaging lipid droplets in Alzheimer\u2019s disease microglia","volume":"628","author":"Haney","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.it.2024.08.001_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/science.add1236","article-title":"ApoE isoform- and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy","volume":"379","author":"Seo","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.it.2024.08.001_bb0240","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41593-022-01127-0","article-title":"Peripheral apoE4 enhances Alzheimer\u2019s pathology and impairs cognition by compromising cerebrovascular function","volume":"25","author":"Liu","year":"2022","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.it.2024.08.001_bb0245","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 leads to blood\u2013brain barrier dysfunction predicting cognitive decline","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.it.2024.08.001_bb0250","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1093\/brain\/awab478","article-title":"APOE4 derived from astrocytes leads to blood\u2013brain barrier impairment","volume":"145","author":"Jackson","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.it.2024.08.001_bb0255","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1038\/s41586-023-05788-0","article-title":"Microglia-mediated T cell infiltration drives neurodegeneration in tauopathy","volume":"615","author":"Chen","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.it.2024.08.001_bb0260","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","article-title":"Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report","volume":"25","author":"Arboleda-Velasquez","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0265","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00401-022-02467-8","article-title":"Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer\u2019s dementia","volume":"144","author":"Sepulveda-Falla","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.it.2024.08.001_bb0270","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cell.2023.11.029","article-title":"APOE3ch alters microglial response and suppresses A\u03b2-induced tau seeding and spread","volume":"187","author":"Chen","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.it.2024.08.001_bb0275","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1038\/s41593-023-01480-8","article-title":"The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation","volume":"26","author":"Nelson","year":"2023","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.it.2024.08.001_bb0280","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc9375","article-title":"APOE3-Jacksonville (V236E) variant reduces self-aggregation and risk of dementia","volume":"13","author":"Liu","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0285","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jamaneurol.2022.1166","article-title":"Association of rare APOE missense variants V236E and R251G with risk of Alzheimer disease","volume":"79","author":"Le Guen","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.it.2024.08.001_bb0290","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1001\/jama.2023.0268","article-title":"Association of African ancestry-specific APOE missense variant R145C with risk of Alzheimer disease","volume":"329","author":"Le Guen","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.it.2024.08.001_bb0295","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/s41467-019-14279-8","article-title":"Exceptionally low likelihood of Alzheimer\u2019s dementia in APOE2 homozygotes from a 5,000-person neuropathological study","volume":"11","author":"Reiman","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.it.2024.08.001_bb0300","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1056\/NEJMoa2308583","article-title":"APOE3 Christchurch heterozygosity and autosomal dominant Alzheimer\u2019s disease","volume":"390","author":"Quiroz","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0305","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuron.2009.06.026","article-title":"The role of apolipoprotein E in Alzheimer\u2019s disease","volume":"63","author":"Kim","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0310","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41422-024-00957-w","article-title":"APOE3ch alleviates A\u03b2 and tau pathology and neurodegeneration in the human APPNL-G-F cerebral organoid model of Alzheimer\u2019s disease","volume":"34","author":"Liu","year":"2024","journal-title":"Cell Res."},{"key":"10.1016\/j.it.2024.08.001_bb0315","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nm.4443","article-title":"Amyloid-\u03b2 plaques enhance Alzheimer\u2019s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation","volume":"24","author":"He","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0320","article-title":"APOE3-R136S mutation confers resilience against tau pathology via cGAS-STING-IFN inhibition","author":"Naguib","year":"2024","journal-title":"bioRxiv"},{"key":"10.1016\/j.it.2024.08.001_bb0325","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2024.1373568","article-title":"APOE3 Christchurch modulates \u03b2-catenin\/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer\u2019s cases","volume":"17","author":"Perez-Corredor","year":"2024","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.it.2024.08.001_bb0330","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.cell.2018.05.003","article-title":"Disease-associated microglia: a universal immune sensor of neurodegeneration","volume":"173","author":"Deczkowska","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.it.2024.08.001_bb0335","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20202717","article-title":"Microglia in Alzheimer\u2019s disease at single-cell level. Are there common patterns in humans and mice?","volume":"218","author":"Chen","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0340","doi-asserted-by":"crossref","first-page":"29862","DOI":"10.1073\/pnas.2010723117","article-title":"Type I interferon remodels lysosome function and modifies intestinal epithelial defense","volume":"117","author":"Zhang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2024.08.001_bb0345","doi-asserted-by":"crossref","first-page":"3542","DOI":"10.1016\/S0021-9258(18)68957-4","article-title":"Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions","volume":"263","author":"Lalazar","year":"1988","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.it.2024.08.001_bb0350","article-title":"Apolipoprotein E recognizes Alzheimer\u2019s disease associated 3-O sulfation of heparan sulfate","volume":"62","author":"Mah","year":"2023","journal-title":"Angew. Chem. Int. Ed. Eng."},{"key":"10.1016\/j.it.2024.08.001_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100715","article-title":"Regulation of tau internalization, degradation, and seeding by LRP1 reveals multiple pathways for tau catabolism","volume":"296","author":"Cooper","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.it.2024.08.001_bb0360","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1016\/j.neuron.2024.02.009","article-title":"Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer\u2019s disease profile and possible mechanisms of disease protection","volume":"112","author":"Almeida","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0365","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1002\/alz.13436","article-title":"APOE Christchurch-mimetic therapeutic antibody reduces APOE-mediated toxicity and tau phosphorylation","volume":"20","author":"Marino","year":"2024","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.it.2024.08.001_bb0370","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1016\/j.neuron.2021.03.024","article-title":"Selective removal of astrocytic APOE4 strongly protects against tau-mediated neurodegeneration and decreases synaptic phagocytosis by microglia","volume":"109","author":"Wang","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0375","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13024-022-00516-0","article-title":"Selective reduction of astrocyte apoE3 and apoE4 strongly reduces A\u03b2 accumulation and plaque-related pathology in a mouse model of amyloidosis","volume":"17","author":"Mahan","year":"2022","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.it.2024.08.001_bb0380","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1084\/jem.20121274","article-title":"Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of A\u03b2 amyloidosis","volume":"209","author":"Kim","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0385","doi-asserted-by":"crossref","first-page":"7281","DOI":"10.1523\/JNEUROSCI.0646-14.2014","article-title":"Anti-ApoE antibody given after plaque onset decreases A\u03b2 accumulation and improves brain function in a mouse model of A\u03b2 amyloidosis","volume":"34","author":"Liao","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.it.2024.08.001_bb0390","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/ana.26043","article-title":"Apolipoprotein E4 reduction with antisense oligonucleotides decreases neurodegeneration in a tauopathy model","volume":"89","author":"Litvinchuk","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.it.2024.08.001_bb0395","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","article-title":"Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of \u03b2-amyloidosis","volume":"96","author":"Huynh","year":"2017","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0400","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1172\/JCI96429","article-title":"Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation","volume":"128","author":"Liao","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.it.2024.08.001_bb0405","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd7522","article-title":"APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function","volume":"13","author":"Xiong","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0410","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1002\/ana.26351","article-title":"APOE antibody inhibits A\u03b2-associated Tau seeding and spreading in a mouse model","volume":"91","author":"Gratuze","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.it.2024.08.001_bb0415","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.neurobiolaging.2022.03.011","article-title":"ApoE4 reduction: an emerging and promising therapeutic strategy for Alzheimer\u2019s disease","volume":"115","author":"Li","year":"2022","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.it.2024.08.001_bb0420","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1016\/j.neuron.2021.05.034","article-title":"Overexpressing low-density lipoprotein receptor reduces tau-associated neurodegeneration in relation to apoE-linked mechanisms","volume":"109","author":"Shi","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0425","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.neuron.2023.10.023","article-title":"Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist","volume":"112","author":"Litvinchuk","year":"2024","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0430","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.85779","article-title":"APOE expression and secretion are modulated by mitochondrial dysfunction","volume":"12","author":"Wynne","year":"2023","journal-title":"Elife"},{"key":"10.1016\/j.it.2024.08.001_bb0435","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.ymthe.2024.03.024","article-title":"APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease","volume":"32","author":"Jackson","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.it.2024.08.001_bb0440","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1089\/humc.2017.231","article-title":"AAVrh.10-mediated APOE2 central nervous system gene therapy for APOE4-associated Alzheimer\u2019s disease","volume":"29","author":"Rosenberg","year":"2018","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.it.2024.08.001_bb0445","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.neuron.2020.09.029","article-title":"Emerging microglia biology defines novel therapeutic approaches for Alzheimer\u2019s disease","volume":"108","author":"Lewcock","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0450","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1016\/j.neuron.2022.10.020","article-title":"Microglia states and nomenclature: a field at its crossroads","volume":"110","author":"Paolicelli","year":"2022","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0455","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/s42003-022-04200-3","article-title":"Development of microglia-targeting adeno-associated viral vectors as tools to study microglial behavior in vivo","volume":"5","author":"Okada","year":"2022","journal-title":"Commun. Biol."},{"key":"10.1016\/j.it.2024.08.001_bb0460","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41592-022-01547-7","article-title":"Directed evolution of adeno-associated virus for efficient gene delivery to microglia","volume":"19","author":"Lin","year":"2022","journal-title":"Nat. Methods"},{"key":"10.1016\/j.it.2024.08.001_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108443","article-title":"Efficient strategies for microglia replacement in the central nervous system","volume":"33","author":"Xu","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.it.2024.08.001_bb0470","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20220857","article-title":"Engineering an inhibitor-resistant human CSF1R variant for microglia replacement","volume":"220","author":"Chadarevian","year":"2023","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0475","doi-asserted-by":"crossref","DOI":"10.1111\/acel.12832","article-title":"Replacement of microglia in the aged brain reverses cognitive, synaptic, and neuronal deficits in mice","volume":"17","author":"Elmore","year":"2018","journal-title":"Aging Cell"},{"key":"10.1016\/j.it.2024.08.001_bb0480","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.66738","article-title":"Subventricular zone\/white matter microglia reconstitute the empty adult microglial niche in a dynamic wave","volume":"10","author":"Hohsfield","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.it.2024.08.001_bb0485","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.neuron.2019.07.002","article-title":"Development of a chimeric model to study and manipulate human microglia in vivo","volume":"103","author":"Hasselmann","year":"2019","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0490","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41591-022-01691-9","article-title":"Hematopoietic stem cell transplantation chemotherapy causes microglia senescence and peripheral macrophage engraftment in the brain","volume":"28","author":"Sailor","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.xpro.2023.102490","article-title":"CRISPR generation of CSF1R-G795A human microglia for robust microglia replacement in a chimeric mouse model","volume":"4","author":"Chadarevian","year":"2023","journal-title":"STAR Protoc."},{"key":"10.1016\/j.it.2024.08.001_bb0500","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/nature10907","article-title":"Wild-type microglia arrest pathology in a mouse model of Rett syndrome","volume":"484","author":"Derecki","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.it.2024.08.001_bb0505","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.stem.2023.07.006","article-title":"A cell therapy approach to restore microglial Trem2 function in a mouse model of Alzheimer\u2019s disease","volume":"30","author":"Yoo","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.it.2024.08.001_bb0510","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl9945","article-title":"Treatment of a genetic brain disease by CNS-wide microglia replacement","volume":"14","author":"Shibuya","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0515","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12974-020-01980-5","article-title":"Engagement of TREM2 by a novel monoclonal antibody induces activation of microglia and improves cognitive function in Alzheimer\u2019s disease models","volume":"18","author":"Fassler","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.it.2024.08.001_bb0520","doi-asserted-by":"crossref","first-page":"11524","DOI":"10.1073\/pnas.1710311114","article-title":"TREM2 deficiency attenuates neuroinflammation and protects against neurodegeneration in a mouse model of tauopathy","volume":"114","author":"Leyns","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2024.08.001_bb0525","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.1084\/jem.20190980","article-title":"Microglia drive APOE-dependent neurodegeneration in a tauopathy mouse model","volume":"216","author":"Shi","year":"2019","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.it.2024.08.001_bb0530","first-page":"937","article-title":"Characterization of five new mutants in the carboxyl-terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia","volume":"52","author":"van den Maagdenberg","year":"1993","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.it.2024.08.001_bb0535","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1750-1326-9-11","article-title":"ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer\u2019s disease","volume":"9","author":"Medway","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.it.2024.08.001_bb0540","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.neuron.2020.10.008","article-title":"Apolipoprotein E: structural insights and links to Alzheimer disease pathogenesis","volume":"109","author":"Chen","year":"2021","journal-title":"Neuron"},{"key":"10.1016\/j.it.2024.08.001_bb0545","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2215371120","article-title":"Apolipoprotein E4 has extensive conformational heterogeneity in lipid-free and lipid-bound forms","volume":"120","author":"Stuchell-Brereton","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.it.2024.08.001_bb0550","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.3233\/JAD-190175","article-title":"Plasma apolipoprotein E monomer and dimer profile and relevance to Alzheimer\u2019s disease","volume":"71","author":"Patra","year":"2019","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.it.2024.08.001_bb0555","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/j.neuron.2023.12.018","article-title":"Apolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins","volume":"112","author":"Strickland","year":"2024","journal-title":"Neuron"}],"container-title":["Trends in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149062400187X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147149062400187X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T20:14:37Z","timestamp":1730492077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147149062400187X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":111,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S147149062400187X"],"URL":"https:\/\/doi.org\/10.1016\/j.it.2024.08.001","relation":{},"ISSN":["1471-4906"],"issn-type":[{"value":"1471-4906","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New insights into innate immunity in Alzheimer\u2019s disease: from APOE protective variants to therapies","name":"articletitle","label":"Article Title"},{"value":"Trends in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.it.2024.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}